ETCTN A Phase 2 Study of Ipatasertib in Combination with Pembrolizumab for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck Adult CIRB - Early Phase Emphasis Active Available to Open